Research Article

The Aryl-Hydrocarbon Receptor Protein Interaction Network (AHR-PIN) as Identified by Tandem Affinity Purification (TAP) and Mass Spectrometry

Dorothy M. Tappenden,1,2 Hye Jin Hwang,1,3 Longlong Yang,4 Russell S. Thomas,4 and John J. LaPres1,2,3

1 Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824-1319, USA
2 Center for Integrative Toxicology, Michigan State University, East Lansing, MI 48824-1319, USA
3 Center for Mitochondrial Science and Medicine, Michigan State University, East Lansing, MI 48824-1319, USA
4 The Hamner Institutes for Health Sciences, Research Triangle Park, NC 27709, USA

Correspondence should be addressed to John J. LaPres; lapres@msu.edu

Received 2 August 2013; Revised 9 October 2013; Accepted 14 October 2013

Copyright © 2013 Dorothy M. Tappenden et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The aryl-hydrocarbon receptor (AHR), a ligand activated PAS superfamily transcription factor, mediates most, if not all, of the toxicity induced upon exposure to various dioxins, dibenzofurans, and planar polyhalogenated biphenyls. While AHR-mediated gene regulation plays a central role in the toxic response to dioxin exposure, a comprehensive understanding of AHR biology remains elusive. AHR-mediated signaling starts in the cytoplasm, where the receptor can be found in a complex with the heat shock protein of 90kDa (Hsp90) and the immunophilin-like protein, aryl-hydrocarbon receptor-interacting protein (AIP). The role these chaperones and other putative interactors of the AHR play in the toxic response is not known. To more comprehensively define the AHR-protein interaction network (AHR-PIN) and identify other potential pathways involved in the toxic response, a proteomic approach was undertaken. Using tandem affinity purification (TAP) and mass spectrometry we have identified several novel protein interactions with the AHR. These interactions physically link the AHR to proteins involved in the immune and cellular stress responses, gene regulation not mediated directly via the traditional AHR:ARNT heterodimer, and mitochondrial function. This new insight into the AHR signaling network identifies possible secondary signaling pathways involved in xenobiotic-induced toxicity.

1. Introduction

Dioxins, a family of toxic chemical compounds that are highly stable and readily bioaccumulate, have been the focus of extensive research for several decades [1, 2]. Investigations have shown that these compounds can arise naturally from forest fires and cooking; however, industrial processes, such as paper bleaching and pesticide manufacturing, produced dioxins in large quantities. This increased production has lead to pervasive environmental contamination. In fact, over 500,000 tons of soil and sediment are contaminated with 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD) in the US alone [3].

TCDD and other dioxins induce a host of toxic responses in mammals, such as thymic involution, immunosuppression, wasting syndrome, and chloracne. The aryl-hydrocarbon receptor (AHR) mediates virtually all of these dioxin-induced pathologies [4, 5]. Studies revealed that dioxins serve as ligands which activate the AHR [6], a member of the basic helix-loop-helix-Per-Arnt-Sim (bHLH-PAS) superfamily of transcription factors [7]. In the absence of ligand, the AHR can be found in the cytosol bound to a dimer of the heat shock protein of 90 kDa, Hsp90, and the immunophilin-like protein, AIP (also known as XAP2 and ARA9) [8, 9]. Upon ligand binding the AHR translocates to
the nucleus and binds its heterodimeric partner, the arylhydrocarbon receptor nuclear translocator (ARNT) protein. The AHR/ARNT dimer regulates expression of a battery of genes involved in metabolism and elimination, including xenobiotic metabolizing enzymes CYP1A1 and CYP1B1 [10, 11]. The translocation and subsequent DNA binding of the AHR is necessary for TCDD-induced toxicity; however, the toxicity associated with dioxin exposure does not directly correlate with the levels of the AHR found in the various tissues [12–16]. In fact, the liver, an organ with relatively high AHR expression, is fairly resistant to TCDD-induced toxicity [17]. This tissue-specific response raises the possibility that accessory factors and secondary signaling are involved in modulating the receptor’s ability to promote toxicity.

Besides Hsp90 and AIP, the AHR also has been shown to interact with p23, Cdk4, the retinoblastoma protein (Rb), and RelA of the NFκB complex [16, 18–20]. Early reports demonstrated that p23 was a core AHR complex protein. The p23 protein has been reported to function in numerous cellular roles including organelle function, DNA repair, and cell mobility [21]. Recently, p23 was shown to specifically interact with the N-terminus of Hsp90 [22]. Other reports have shown its interaction with the AHR to be transient and nonessential for the receptor’s function [23, 24]. The interactions with Cdk4, Rb, and RelA link the receptor to cell cycle, kinase signaling, and gene regulation not exclusively mediated by the AHR. Moreover, the AHR has been implicated in estrogen and glucocorticoid receptor signaling and developmental processes [25–27]. Taken together, this multifaceted interaction network suggests that AHR biology is complex and capable of impacting several cellular responses.

The extent of the AHR protein interaction network (AHR-PIN) has not been addressed on a proteomic level in a mammalian system. To investigate the role that protein-protein interactions have in AHR-mediated dioxin toxicity, we have established the AHR-PIN using tandem affinity purification (TAP) and mass spectrometry (MS). Here we report the AHR-PIN as assembled from MS data collected in the presence and absence of TCDD ligand, using a Hepalcl7 cell line with stable overexpression of an AHR-TAP-tagged construct [28]. The Hepalcl7 cell line is extensively used in AHR research and well characterized in its responses to TCDD exposure. Although the liver is not considered highly sensitive to TCDD-induced toxicity, the tissue does experience marked changes in gene expression, hyperlipidemia, and hepatosteatosis [29]. Defining the AHR-PIN in this cell line offers insights to how TCDD influences AHR biology and induces toxicity in this tissue type. Identified AHR interactors include mitochondrial, cell cycle, immune response, and transcription factor proteins. The new AHR-PIN has identified different secondary pathways that could potentially influence TCDD-induced AHR-mediated toxicity. Previously, we reported AHR’s influence on mitochondrial function through its interaction with the ATP5e1 subunit of the ATP synthase complex [28]. Here we focus on the receptor’s interaction with another mitochondrial protein, mitochondrial ribosomal protein L40 (Mrpl40).

2. Materials and Methods

2.1. Materials. Oligonucleotides were synthesized at the Macromolecule Synthesis Facility at Michigan State University. The pTarget and pGEM-T Easy vectors were purchased from Promega (Madison, WI) and pZome1C vector was obtained from Cellzome (Cambridge, UK). Antibodies used in these experiments were obtained from the following resources; rabbit polyclonal anti-AHR antibodies were a generous gift from Dr. Christopher Bradfield (University of Wisconsin-Madison), rabbit anti-Mrpl40 (cat no. HPA006181) was purchased from Sigma (St Louis, MO), mouse anti-COX4 (cat no. A21348) was purchased from Life Technologies (Grand Island, NY), goat anti-rabbit (cat no. sc2004), goat anti-mouse (cat no. sc2005), normal rabbit IgG (cat no. sc2027) and protein G resin were obtained from Santa Cruz (Santa Cruz, CA). All other chemicals used in these experiments were reagent grade and purchased from Sigma Aldrich (St. Louis, MO).

2.2. Plasmid Constructs and Cell Culture. The cDNAs for the murine AHR and the green fluorescent protein (GFP) were amplified using the following primers.

AHR: 5′-ggatccccagacaacagcaccgagcagcagtaccttc-3′ and 5′-ggatccccccagcaccgagcagcagtaccttc-3′, GFP: 5′-ggggatcactcactccatgtgagttgtgcagct-3′ and 5′-ggggatcactcactccatgtgagttgtgcagct-3′. The amplicons were subcloned into pZome1C vector placing the TAP-tag at the C terminal of both the AHR and GFP genes. Ampicillin resistance was used for clonal selection and each positive clone was sequence verified. Phoenix-eco and Hepalcl7 cells were cultured in DMEM high glucose media with L-glutamate and supplemented with 10% cosmetic calf serum (CCS), 100 units/mL penicillin, 100 μg/mL streptomycin, and 1 mM sodium pyruvate. HepaCl2 cells were cultured in DMEM high glucose media w/ L-glutamate and supplemented with 10% cosmetic calf serum (CCS), and 1 mM sodium pyruvate. Tissue culture media and supplements were obtained from Life Technologies and CCS was obtained from HyClone (Waltman, MA). Hepalcl7 TAP, AHR and TAP-GFP were grown in the media described above and puromycin (2 μg/mL, US Biological, Swampscott, MA) was used for selection.

2.3. Transfection/Stable Cell Line Infection. The retroviral vectors, AHR-TAP and GFP-TAP, were transfected into Phoenix-eco cells with Lipofectamine 2000 (Life Technologies) via manufacturer’s instructions. After incubation (5 to 8 hours, 37°C) in the presence of DNA, the media were changed to Phoenix cell growth media containing chloroquine (25 μM). Cells were then incubated for 24 hours (37°C). After incubation, cells were given fresh Phoenix cell growth media and incubated for an additional 24 hours (32°C). The media were collected after incubation; centrifugation was used to remove cellular debris (3 mins, 45 xg, in RT7 Sorvall, Rockford, IL), and the media were purified using a 0.45 μm membrane filter (Millipore). Virus containing media was placed on Hepalcl7 wild type target cell lines and incubated for 3 hrs at 32°C and 5% CO2. Media containing 15 μg/mL polybrene were then added to target cells and
incubated for 24 hours (32°C). After incubation, fresh media were added to target cells and incubated (37°C) until plates reached 80% confluence. Cells were passaged and selected using puromycin (2 µg/mL).

2.4. Western Blot Analysis. Tissue culture samples were harvested and total protein concentration was determined as previously described [30]. Proteins samples were separated on Nu-Page Bis-Tris 4–12% gradient gels, transferred to nitrocellulose membranes, and probed with assorted antibodies as previously described [31]. Western blots were visualized using Pierce (Rockford, IL) ECL western blotting substrate.

2.5. Tandem Affinity Purification. An estimated 2.5 × 10^9 Hepa1c1c7 TAP-AH and TAP-GFP cell were challenged with DMSO (vehicle control, 0.01%) or TCDD (10 nM) for 30, 120, or 240 minutes in 3 independent experiments (Figure 1(a)). Media were removed and cells were washed three times in cold phosphate buffered saline (PBS). Cells were harvested in TAP-tag lysis buffer (TTLB, 5% glycerol, 50 mM Tris, pH 7.5, 50 mM MgCl2, 100 mM NaCl, 0.1% NP40, 1 mM EDTA, 1 mM Na3VO4, 25 mM NaF, and protease inhibitor tablets) and lysed by two cycles of freeze/thaw, and insoluble material was removed by centrifugation (7000 x g, 20 mins). Next, samples were incubated with 200 µL of IgG Sepharose beads (GE Healthcare, Waukesha, WI) for 4 hrs, at 4°C and rotation. Beads were collected by centrifugation (45 x g, 30 sec) and transferred to Poly-Prep Chromatography columns (BioRad, Hercules, CA). Beads were extensively washed with TAP-tag lysis buffer and then with TEV cleavage buffer (10 mM Tris, pH 7.5, 150 mM NaCl, 0.1% NP40, 0.5 mM EDTA, and 1 mM DTT). IgG beads were incubated (18 hrs, 4°C) in 1.5 mL TEV cleavage buffer containing AcTEV protease (450 units). Eluates were collected by gravity flow. Beads were washed with 1.5 mL of TEV buffer and 9 mL of calmodulin binding buffer (CBB) (10 mM β-mercaptoethanol, 10 mM Tris, pH 7.5, 150 mM NaCl, 1 mM MgOAc, 1 mM imidazole, 0.1% NP40, and 2 mM DTT). Elute and washes were combined. Samples were then incubated with 200 µL calmodulin affinity resin (Stratagene, La Jolla, CA) (4 hrs, 4°C). After incubation, calmodulin resin was transferred to new Ploy-Prep Chromatography columns, and resin was washed extensively with CBB. Warm 3X SDS buffer (4.8% SDS, 100 mM Tris pH 6.8, 16% glycerol, 8% β-mercaptoethanol, and 0.4% bromophenol blue) was used to elute protein complexes from resin (Figure 1(b)).

2.6. Gel Electrophoresis and Mass Spectrometry. Samples were separated on a 4–12% Bis–Tris gradient gel (NuPage, Invitrogen) by electrophoresis. SilverSNAP staining kit (Pierce, Rockford, IL) was used to visualize proteins according to manufacturer’s protocol and the gel was photographed (Figure 1(c)). Specific protein bands were excised from the gel matrix, destained with SilverSNAP destaining kit (Pierce, Rockford, IL), and subjected to in-gel tryptic digestion as previously described [32] (Figure 1(d)). The extracted peptides were then automatically injected by a Waters nanoACQUITY Sample Manager (Milford, MA) loaded for 5 minutes onto a Waters Symmetry C18 peptide trap (5 µm, 180 µm x 20 mm) at 4 µL/min in 5% acetonitrile/0.1% formic acid. The bound peptides were eluted onto a Waters BEH C18 nanoACQUITY column (1.7 µm, 100 µm x 100 mm) over 35 minutes with a gradient of 2% B to 35% B in 21 min, 90% B from 21–24 min, and back to constant 5% B at 24.1 min using a Waters nanoACQUITY UPLC (buffer A = 99.9% water/0.1% formic acid, buffer B = 99.9% acetonitrile/0.1% formic acid) with an initial flow rate of 600 nL/min, ramping to 700 nL/min at 80 min and back to 600 nL/min at 86 min. Eluted peptides were sprayed into a Thermo Fisher LTQ Linear Ion trap mass spectrometer outfitted with a MICHROM Bioresources ADVANCE nanospray source. The top five ions in each survey scan are then subjected to data-dependent zoom scans followed by low energy collision induced dissociation (CID) and the resulting MS/MS spectra are converted to peak lists using BioWorks Browser v 3.3.1 (Thermo Fisher, Rockford, IL) using the default LTQ instrument parameters. Peak lists were searched against all mouse sequences available in the NCBI nr database, downloaded on November 16, 2008, from NCBI, using the Mascot searching algorithm, v2.2 (http://www.matrixscience.com/). The Mascot output was then analyzed using Scaffold (http://www.proteomsoftware.com/) to probabilistically validate protein identifications using the ProteinProphet computer algorithm (Figure 1(e)).

2.7. Coimmunoprecipitation. Wild type Hepal1c1c7 cells were grown to 80% confluence. Media were removed and cells were washed with ice cold PBS and then harvested with TTTLB. Cellular supernatants (500 µg) were incubated with normal rabbit IgG (2 µg/µL) or an anti-AHR antibody (2 µg/µL) for 90 minutes. Following incubation, protein G beads (30 µL) were added to the samples and incubated for an additional 90 minutes. Beads were collected by centrifugation. The supernatant was removed, and the beads were washed extensively in TTTLB. Samples were eluted from the beads with warm 3X SDS buffer and separated on a Nu-PAGE Bis-Tris 4–12% gradient gel matrix, transferred to nitrocellulose membrane, and probed with primary AHR or Mrpl40 antibodies.

2.8. Cellular Fractionation. Wild type Hepal1c1c7 and AHR null HepaC12 cell lines were treated with vehicle (0.01% DMSO) or TCDD (10 nM) for 6 hrs. After treatment cells were harvested using fractionation buffer (25 mM sucrose, 20 mM Tris-HCl, 1 mM EDTA, pH7.4). The cells underwent one round of freeze/thaw and then dounce homogenized (100 strokes). Insoluble materials were removed by centrifugation (400 x g, 10 min) and the supernatant was transferred to a new tube. An aliquot of this supernatant was taken as the whole cell lysate (WLC) fraction. Separation of the supernatant and organelle fractions was performed by centrifugation (4,500 x g, 10 min). The supernatant was removed and an aliquot was taken as the cytosolic fraction (Cyto). The organelle pellet was resuspended in 1 mL of fractionation buffer and dounce homogenized (14–20 strokes). An aliquot of the pellet after resuspension and homogenization was taken as the impure mitochondrial fraction (MFI). Large debris was removed from the MFI sample by centrifugation (400 x g, 10 min). The supernatant was transferred to a new tube and mitochondria were isolated by centrifugation.
Figure 1: Experimentation overview. (a) Schematic outline of TCDD exposure experiments in Hepa1c1c7 cell lines. GFP and AHR samples were treated with vehicle (DMSO (D), 0.01%); the remaining three AHR samples were treated with TCDD (10 nM) for the labeled time (30, 120, and 240 mins). (b) Schematic of the tandem affinity purification (TAP) protocol. After TCDD exposure, cell lysate samples underwent two rounds of purification utilizing the TAP methodology. AHR and GFP TAP-tagged proteins and their associated complexes were isolated and then separated using gel electrophoresis. (c) Representative image of gel replicates for final TAP eluate samples separated in 4–12% Nu-page gel matrix. Boxes around the areas of the AHR-TAP 240 min TCDD dose sample lane denote the areas of the gel that were excised from each of the sample lanes. (d) Schematic of the in-gel trypsin digestion protocol. Excised gel samples were destained, and proteins underwent reduction, alkylation, and trypsin digestion. (e) Sample of MS analysis data set. Lastly, the protein fragment samples then underwent MS analysis as described in Section 2.
(4,500 xg, 10 min). The mitochondrial pellet was resuspended in 100 μL fractionation buffer and is the pure mitochondrial fraction (MF2).

3. Results

3.1. Workflow for Proteomic Screen. Each replicate of the proteomic screen was processed following the workflow described in Figure 1 and detailed in the materials and methods section.

3.2. Identification of AHR Interactors. TAP was performed on DMSO treated GFP-TAP and AHR-TAP cells and AHR-TAP Hepa1c1c7 samples treated with TCDD (10 nM) for different times (30, 120, 240 minutes), followed by MS analysis of the TAP final eluates. The cytosolic partners of the AHR, Hsp90α, Hsp90β, and AIP were identified in the AHR-TAP sample at a greater than 95% confidence. The identification of the core AHR cytosolic complex proteins demonstrates that this method is a valid means to investigate novel AHR protein interactions.

TCDD and vehicle treated AHR-TAP Hepa1c1c7 samples from three separate experiments, per treatment and time point, were analyzed for AHR protein interactors. The GFP-TAP vehicle treated sample data sets were used as a negative control. The TAP samples were separated into discrete bands in a gel matrix and excised for MS analysis (Figure 1(c)). The breakdown of proteins identified per treatment group is as follows. There are 74 proteins identified in the vehicle treatment group of which 13 were identified in 2 or more replicate samples: 4 novel proteins, 4 known interactors, and 5 nonspecific interactors (Figure 2). The 30-minute TCDD treatment groups contained 66 proteins, including 12 that were identified in 2 or more of the replicates: 6 novel proteins, 2 known interactors, and 4 nonspecific interactors (Figure 3). The smallest protein set, a total of 51 proteins, was identified in the 120-minute TCDD treatment groups. This group contained 10 proteins that were identified in 2 or more replicates: 6 novel interactors, 1 known interactor, and 3 nonspecific interactors (Figure 4). Lastly, the 240-minute TCDD treatment data set contains 59 proteins, of which 14 were identified in multiple replicates: 10 novel interactors, no known interactors, and 4 nonspecific interactors (Figure 5). Here, novel proteins are considered previously unreported AHR interactions; some of these novel proteins were found in more than one data set and will be discussed below. The group of previously reported proteins included Hsp90 isoforms, Hsp90α and Hsp90β, AIP, and the ATP synthase Fl complex, alpha subunit (ATP5α1). Nonspecific interactors were found in both the AHR-TAP and GFP-TAP sample data sets and will not be discussed further. The unique proteins of these data sets are detailed below.

In the DMSO treated AHR-TAP samples two proteins are exclusive to this data set (Figure 2). One is the previously reported ATP5α1 subunit of the ATP synthase complex [28]. The other is Tesp4, a ubiquitously expressed homolog of pancreatic trypsin [33]. One protein, Mrpl40, was also identified in the 30- and 240-minute TCDD treatment samples. In yeast, this protein has been shown to play a role in growth rate, mitochondrial protein folding, and mitochondrial function [34, 35]. In humans, the Mrpl40 gene is part of a chromosomal deletion of 22q11 in velo-cardio-facial syndrome (VCFS) and DiGeorge syndrome [36, 37]. The remaining two proteins, cardiotoxin-like cytokine factor 1 (Clcfl) and HIV TAT specific factor 1 (Htatsfl), were identified in this and all three (30, 120, 240 minute) TCDD treatment data sets. Clcfl is a cytokine, highly expressed in tissues of the immune system, and is an activator of kinase pathways [38, 39]. Htatsfl is a transcriptional cofactor that regulates expression of the HIV-1 LTR [40].

The 30-minute TCDD treated AHR-TAP sample sets contained one protein exclusive to this treatment set, the cAMP responsive element binding protein 3-like 3 (Creb3l3) (Figure 3). Creb3l3, which is also known as CrebH, functions as an endoplasmic reticulum bound transcription factor responsible for regulating hepatic gluconeogenesis [41]. Two of these proteins, Enhancer-trap locus-1 (Smarcd SWI/SNF-related) and Euaryotic translation elongation factor 1 alpha 1 (Eef1a1), were identified in all three of the TCDD treated sample sets. Smarcd functions as a DNA helicase associated with SWI/SNF complexes [42]. Eef1a1 facilitates protein synthesis through tRNA transfer to ribosomal machinery [43]. The remaining three proteins in this sample set, Mrpl40, Clcfl, and HIV TAT, were introduced above.

There were no unique proteins to the 120 minute TCDD treated AHR-TAP sample data sets. There are two proteins in common between this and the 240 minute TCDD treated data sets, an uncharacterized transcript, hypothetical protein LOC56279, and the activated leukocyte cell adhesion molecule CD166 (Alcam) (Figure 4). Alcam has become widely recognized as a cellular marker for several forms of cancer, including melanoma, squamous cell carcinoma, prostate, breast, colorectal, bladder, esophageal, and ovarian cancers [44–46]. The four remaining proteins of these data sets, Smarcd, Eef1a1, Clcfl, and HIV TAT, have been discussed above.

There were three unique proteins to the 240 minute TCDD treatment AHR-TAP samples, Bc12-associated anathogene 3 (Bag3), ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 (Asap2), and ubiquitin associated protein 2-like (Ubap2) (Figure 5). Bag3, the second mitochondrial associated protein identified, is a chaperone protein involved in the stress response and disease [47, 48]. Bag3 is considered a prooncoprotein, by inhibiting the apoptotic response through its influence on Bcl-2 family members [49, 50]. Asap2, also known as development and differentiation enhancing factor 1 (Ddef1), is an Arf-GTPase activating protein [51, 52]. Ubap2 is associated with proteasome mediated protein degradation and has been implicated in infertility [53]. The seven remaining proteins identified in these data sets were introduced in the previous data sets.

3.3. Coimmunoprecipitation Verification of Identified Interactors. Independent verification of the interactions between the AHR and select proteins identified by mass spectrometry was performed by coimmunoprecipitation in wild type Hepa1c1c7 cells. Similar to previously reported verification of the AHR:ATP5α1 interaction [28], this method was used to investigate the interaction between the AHR and Mrpl40
Figure 2: DMSO control data set. (a) Venn diagram of proteins identified by mass spectrometry in 3 data sets of AHR-TAP DMSO (0.01%) control. (b) Table listing of proteins identified in two out of three data sets. Bold type with * denotes a protein represented in all three data sets. Italicized type denotes nonspecific proteins identified in both AHR-TAP and GFP-TAP samples.

Figure 3: TCDD 30-minute treatment data set. (a) Venn diagram of proteins identified by mass spectrometry in 3 data sets of AHR-TAP 30 min TCDD (10 nM) dosing. (b) Table listing of proteins identified in two out of three data sets. Bold type with * denotes a protein represented in all three data sets. Italicized type denotes nonspecific proteins identified in both AHR-TAP and GFP-TAP samples.

(Figure 6). Mrpl40 was chosen to further investigate the direct link between the AHR and mitochondrial function that was recently reported [28]. Mrpl40 showed marked enrichment in the AHR Co-IP samples over the normal mouse IgG control. These interactions were reproducible in at least two of the three trials performed. The functional consequence of these interactions is currently under investigation.

3.4. TCDD Influence on MRPL40 Cellular Localization. We previously reported that TCDD exposure decreased the pool of AHR in the mitochondrial but did not alter ATP5α1 levels [28]. Given AHR's interaction with MRPL40, we wanted to determine if TCDD-induced depletion of mitochondrial localized AHR impacted the cellular localization of MRPL40. To investigate this, cellular fractionation was performed on wild type Hepa1c1c7 cells treated with TCDD (10 nM) and vehicle (DMSO) for 6 hrs (Figure 7(a)). A marked decrease in mitochondrial MRPL40 levels was observed in the 6 hr TCDD treatment samples. Next we examined the localization of Mrpl40 in the AHR null cell line, HepaC12. The AHR null cell line does not experience a decrease in mitochondrial Mrpl40 levels in the presence of TCDD (Figure 7(b)).
Figure 4: TCDD 120-minute treatment data set. (a) Venn diagram of proteins identified by mass spectrometry in 3 data sets of AHR-TAP 120 min TCDD (10 nM) dosing. (b) Table listing of proteins identified in two out of three data sets. Bold type with * denotes a protein represented in all three data sets. Italicized type denotes nonspecific proteins identified in both AHR-TAP and GFP-TAP samples.

| Protein                                           | Official symbol | Entrez number |
|---------------------------------------------------|-----------------|---------------|
| Activated leukocyte cell adhesion molecule CD166*  | Alcam           | 11658         |
| Cardiotrophin-like cytokine factor 1               | Clcf1           | 56708         |
| Smarcd1 SWI/SNF-related                            | Smarcd1         | 13990         |
| Eef1a1 eukaryotic translation elongation factor 1 alpha 1 | Eef1a1         | 13627         |
| Heat shock protein 1, beta                         | Hsp90ab1        | 15516         |
| HIV TAT specific factor 1                          | Htatsf1         | 72459         |
| Hypothetical protein LOC56279                     |                 | 56279         |
| Hippocalcin-like 1*                                | Hpcal1          | 53602         |
| Interferon gamma inducing factor                   | Il18            | 16173         |
| Unnamed protein*                                   | A430108E01Rik   | 384382        |

Figure 5: TCDD 240-minute treatment data set. (a) Venn diagram of proteins identified by mass spectrometry in 3 data sets of AHR-TAP 240 min TCDD (10 nM) dosing. (b) Table listing of proteins identified in two out of three data sets. Bold type with * denotes a protein represented in all three data sets. Italicized type denotes nonspecific proteins identified in both AHR-TAP and GFP-TAP samples.

| Protein                                           | Official symbol | Entrez number |
|---------------------------------------------------|-----------------|---------------|
| Activated leukocyte cell adhesion molecule CD166*  | Alcam           | 11658         |
| Cardiotrophin-like cytokine factor 1               | Clcf1           | 56708         |
| Bcl2-associated athanogene 3                      |                 |               |
| Smarcd1 SWI/SNF-related                            | Smarcd1         | 13990         |
| Arf-GAP with SH3 domain, ankyrin repeat and PH domain containing protein 2 | Asap2          | 211914        |
| Eef1a1 eukaryotic translation elongation factor 1 alpha 1 | Eef1a1         | 13627         |
| HIV TAT specific factor 1                          | Htatsf1         | 72459         |
| Hypothetical protein LOC56279                     |                 | 56279         |
| Mitochondrial ribosomal protein L40               | Mrpl40          | 18100         |
| Ubiquitin associated protein 2-like                | Ubap2l          | 74383         |
| Alpha-tubulin isotype M-alpha-2                   | Tuba 1b         | 22143         |
| Hippocalcin-like 1                                | Hpcal1          | 53602         |
| Interferon gamma inducing factor                   | Il18            | 16173         |
| Unnamed protein product                            | A430108E01Rik   | 384382        |

Figure 6: Independent protein interaction verification. Coimmunoprecipitations (Co-IP) using anti-AHR or normal rabbit IgG as negative control were performed in wild type Hepa1c1c7 cells. (a) Western blot probed with anti-MRPL40 (Invitrogen). (b) Positive control, western blot probed with anti-AHR. MRPL40 and AHR control all show marked enrichment in the AHR pulldown lanes over the IgG control lane.
Figure 7: TCDD treatment influences Mrpl40 mitochondrial localization. (a) Cellular fractionation was performed on AHR in wild type Hepa1c1c7 cells. Fractions from cells exposed to TCDD for 6 hours were probed with antibodies specific to MRPL40, lactate dehydrogenase (LDH), and cytochrome c oxidase subunit 4 (COX IV). The results demonstrate a decreased level of mitochondrial localized Mrpl40 following TCDD exposure. (b) Similar cellular fractionations were next performed on AHR null HepaC12 cells. No decrease in Mrpl40 was observed after exposure to TCDD for 6 hours. LDH was used as the cytosolic fraction control protein and COX IV was used as the purified mitochondrial fraction control protein.

4. Discussion

The AHR's functional relevance is centered on sensing environmental pollutants and regulating developmental processes. Identifying interacting partners for the AHR, therefore, is important to our understanding of the receptor-mediated changes in signaling pathways involved in these processes. The research detailed here represents the first comprehensive analysis of the AHR-PIN in a mammalian system using proteomic technology. The AHR-PIN reveals physical interactions with proteins involved in several cellular processes and disease states with which the receptor has been previously linked. These include cell cycle, apoptosis, immune response, mitochondrial function, and cancer [16, 54–58]. In addition to AHR mediated gene regulation, this data suggests the receptor's potential influence on cellular biology through protein:protein interactions.

A 2004 study conducted using S. cerevisiae yeast as a model system reported 54 genes which influence AHR biology [59]. Interestingly, we have identified proteins that demonstrate some correlation with this data. In yeast, SNF12 and SWI3 were shown to influence the AHR and here we report a protein interaction between the AHR and SMAD-CAD, a helicase linked to the SWI/SNF complex. In addition, similar to the identified yeast genes encoding kinases and GTPases, we identified several proteins involved in kinase signaling, including Asap2 and Clcf1. While these similarities are not direct correlations, they do provide another layer of evidence to the complexity of AHR biology and the possible mechanisms involved in AHR mediate toxicity and cellular function.

There are previously reported AHR protein interactions that were not observed here that are of note. The cytosolic complex protein p23 was not identified in any of our MS data as stated earlier. Given the transient nature of its interaction with the AHR its absence is not wholly unexpected. We also did not identify Rb or RelA in any of the data sets. These interactions are also of a transient nature, making identification difficult and we cannot rule out cell type-specific interactions [19, 60]. Moreover, it is possible that the level of these proteins' interaction with the AHR is below the detection limit of this methodology as well. Interestingly, we did identify Cdk4 in some of our MS data; however, this result was not consistent across multiple data sets, but the findings correlate with earlier reports of AHR:CDK4 crosstalk [16]. Finally, the AHR's nuclear partner, ARNT, was detected in various TCDD samples across the dosing time course. The ARNT detected, however, did not meet our threshold cutoff (>80% confidence in two or more samples) in a given time point to be included in the tables. This is most likely due to the inherent variability in the assay and the transient nature of the interaction.

The absence of these known interactors and the variability in the data sets were also noted. This type of variability is not unexpected given that many of the proteins were near the limit of detection of the methodology. It is difficult to determine significant differences between samples as one operates closer to the limit of detection [61]. This increased variability might also be involved in the transient identification of some of the identified interactors. For example, Mrpl40 was identified in every sample except the 120-minute one. This might be biologically important or it might be
due to the inherent variability in the methodology and the limitations, in terms of sample size and ability to detect low abundant proteins. This experimental variability might also be confounded by the overexpression system used in this screen. It is difficult, however, to determine the extent to which overexpression has influenced the observations. In addition, the transient nature and complex sample handling protocol will also induce significant amounts of variability between samples. For data analysis of novel AHR protein interactions, we relaxed the confidence level to 80% cutoff. This was done to include proteins that were identified at a greater than 95% confidence in at least one replicate experiment but not all replicates. It should be noted that the variability seen in this screen is consistent with previous published reports for 14-3-3 and c-Myc TAP experiments [62, 63]. Finally, given the inherent variability in this type of analysis, it is as important to investigate the biological importance of those interactions that occurred in a single sample with high significance as it is to investigate those that occurred in multiple replicates.

Previous studies have linked TCDD exposure to mitochondrial dysfunction, including hyperpolarization of the inner membrane, influence on ATP levels, and ROS production [57, 64, 65]. The AHR:ATP5α1 interaction and an AHR-dependent hyperpolarization of the mitochondrial inner membrane that was independent of transcription indicate a role for the AHR in mitochondrial function and cellular energetic [28]. Taken together the novel interaction between the AHR and two other mitochondrial associated proteins are of great interest. The first, Bag3, a prooncoprotein, is involved in the mitochondrial stress response and disease [47, 48]. It has also been shown to inhibit the apoptotic response through interactions with Bcl-2 family members [49, 50]. Moreover, there is evidence that it influences the NFκB pathway through its interaction with p65. The interaction between Bag3 and p65 plays a role in the human immunodeficiency virus type 1 (HIV-1) LTR response to NFκB signaling [66]. The physical interactions between Bag3 and the AHR provide an interesting connection between the AHR and cell cycle regulation, apoptosis, and the NFκB pathway [20]. AHR's interaction with Bag3 observed after the longest TCDD treatment could indicate a mechanism by which activated receptor influences apoptotic signaling cascades. The second, Mrpl40, influences growth rate, mitochondrial protein folding, and mitochondrial function in yeast [34, 35]. It is linked to two diseases in humans, v elo-cardio-facial and DiGeorge syndromes [36, 37]. Interestingly, these diseases present with heart defects and immune deficiencies. AHR null mice have been shown to have abnormal heart development. Furthermore, the immune system is one of the more sensitive to TCDD-induced toxicity [67–69]. We have currently focused more, the immune system is one of the more sensitive to TCDD-induced toxicity [67–69]. We have currently focused our MS studies. Cellular fractionation experiments demonstrated a decreased mitochondrial pool of Mrpl40 after TCDD treatment in AHR expressing hepatoma cells. This decrease in mitochondrial Mrpl40 was not observed in the AHR null hepatoma cell line. It is noteworthy that the decreased mitochondrial pool of Mrpl40 is observed at the same TCDD exposure time point, 6 hrs, as we observed the increase in membrane polarization previously reported [28].

The novel interactions reported here demonstrate potential roles for the AHR in signaling pathways which may function in concert with AHR-mediated gene regulation in dioxin induced toxicity. While the physical interactions reported here provide another layer of evidence for the AHR's potential roles in several signaling pathways, disease states, and gene regulation events, the functional relevance of these interactions remains in question. This AHR-PIN presents new avenues of investigation to better define a comprehensive understanding of AHR biology.

Acknowledgments

The authors would like to thank Drs. Christopher Bradfield and Garry Nolan for their willingness to share cell lines and reagents. This work was supported by NIH Grant P42 ES04911.

References

[1] A. Poland and E. Glover, “Chlorinated dibenzo p dioxins: potent inducers of δ aminolevulinic acid synthetase and aryl hydrocarbon hydroxylase. II. A study of the structure activity relationship,” Molecular Pharmacology, vol. 9, no. 6, pp. 736–747, 1973.

[2] J. C. Knutson and A. Poland, “2,3,7,8-tetrachlorodibenzo-p-dioxin: toxicity in vivo and in vitro,” in Toxicity of Halogenated Hydrocarbons, M. A. A. Khan and R. H. Stanton, Eds., pp. 187–201, Pergamon Press, New York, NY, USA, 1981.

[3] P. Haglund, “Methods for treating soils contaminated with polychlorinated dibenzo-p-dioxins, dibenzofurans, and other polychlorinated aromatic compounds,” Ambio, vol. 36, no. 6, pp. 467–474, 2007.

[4] J. V. Schmidt, G. H. T. Su, J. K. Reddy, M. C. Simon, and C. A. Bradfield, “Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 13, pp. 6731–6736, 1996.

[5] A. Poland and E. Glover, “Characterization and strain distribution pattern of the murine Ah receptor specified by the Ah-like and Ahb-like alleles,” Molecular Pharmacology, vol. 38, no. 3, pp. 306–312, 1990.

[6] R. S. Pollenz, C. A. Sattler, and A. Poland, “Characterization of the Ah receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin: use of chemical crosslinking and a monoclonal antibody directed against a 59-kDa protein associated with steroid receptors,” Molecular Pharmacology, vol. 45, no. 3, pp. 428–438, 1994.

[7] R. Robles, Y. Morita, K. K. Mann et al., “The aryl hydrocarbon receptor, a basic helix-loop-helix transcription factor of the PAS gene family, is required for normal ovarian germ cell dynamics in the mouse,” Endocrinology, vol. 141, no. 1, pp. 450–453, 2000.

[8] L. A. Carver, V. Jackiw, and C. A. Bradfield, “The 90-kDa heat shock protein is essential for Ah receptor signaling in a yeast
expression system," *The Journal of Biological Chemistry*, vol. 269, no. 48, pp. 30109–30112, 1994.

[9] L. A. Carver, J. J. LaPres, S. Jain, E. E. Dunham, and C. A. Bradfield, "Characterization of the Ah receptor-associated protein, ARA9," *The Journal of Biological Chemistry*, vol. 273, no. 50, pp. 33580–33587, 1998.

[10] D. W. Nebert, S. A. Atlas, T. M. Guenthner, and R. E. Kouri, "The Ah locus: genetic regulation of the enzymes which metabolize polycyclic hydrocarbons and the risk for cancer," in *Polycyclic Hydrocarbons and Cancer: Chemistry, Molecular Biology and Environment*, P. O. P. Tso and H. V. Gelboin, Eds., p. 345, Academic Press, New York, NY, USA, 1978.

[11] D. W. Nebert, A. L. Roe, M. Z. Dieter, W. A. Solis, Y. Yang, and T. P. Dalton, "Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis," *Biochemical Pharmacology*, vol. 59, no. 1, pp. 65–85, 2000.

[12] M. K. Bunger, E. Glover, S. M. Moran et al., "Abnormal liver development and resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity in mice carrying a mutation in the DNA-Binding domain of the aryl hydrocarbon receptor," *Toxicological Sciences*, vol. 106, no. 1, pp. 83–92, 2008.

[13] M. K. Bunger, S. M. Moran, E. Glover et al., "Resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity and abnormal liver development in mice carrying a mutation in the nuclear localization sequence of the aryl hydrocarbon receptor," *The Journal of Biological Chemistry*, vol. 278, no. 20, pp. 17767–17774, 2003.

[14] L. A. Carver, J. B. Hogenesch, and C. A. Bradfield, "Tissue specific expression of the rat Ah-receptor and ARNT mRNAs," *Nucleic Acids Research*, vol. 22, no. 15, pp. 3038–3044, 1994.

[15] A. B. Okey, "An aryl hydrocarbon receptor Odyssey to the shores of toxicology: the deichmann lecture, international congress of toxicology-XI," *Toxicological Sciences*, vol. 98, no. 1, pp. 5–38, 2007.

[16] M. A. Barhoover, J. M. Hall, W. F. Greenlee, and R. S. Thomas, "Aryl hydrocarbon receptor regulates cell cycle progression in human breast cancer cells via a functional interaction with cyclin-dependent kinase 4," *Molecular Pharmacology*, vol. 77, no. 2, pp. 195–201, 2010.

[17] H. I. Swanson and C. A. Bradfield, "The AH-receptor: genetics, structure and function," *Pharmacogenetics*, vol. 3, no. 5, pp. 213–230, 1993.

[18] K. A. Hutchison, L. F. Stancato, J. K. Owens-Grillo et al., "The 23-kDa acidic protein in reticulocyte lysate is the weakly bound component of the hsp foldosome that is required for assembly of the glucocorticoid receptor into a functional heterocomplex with hsp90," *The Journal of Biological Chemistry*, vol. 270, no. 32, pp. 18841–18847, 1995.

[19] N. L. Ge and C. J. Elferink, "A direct interaction between the aryl hydrocarbon receptor and retinoblastoma protein: linking dioxin signaling to the cell cycle," *The Journal of Biological Chemistry*, vol. 273, no. 35, pp. 22708–22713, 1998.

[20] Y. Tian, S. Ke, M. S. Denison, A. B. Rabson, and M. A. Gallo, "Ah receptor and NF-κB interactions, a potential mechanism for dioxin toxicity," *The Journal of Biological Chemistry*, vol. 274, no. 1, pp. 510–515, 1999.

[21] F. J. Echtenkamp, E. Zelln, E. Oxelmark et al., "Global functional map of the p23 molecular chaperone reveals an extensive cellular network," *Molecular Cell*, vol. 43, no. 2, pp. 229–241, 2011.

[22] G. E. Karagöz, A. M. S. Duarte, H. Ippel et al., "N-terminal domain of human Hsp90 triggers binding to the cochaperone p23," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 2, pp. 580–585, 2011.

[23] M. B. Cox and C. A. Miller III, "Cooperation of heat shock protein 90 and p23 in aryl hydrocarbon receptor signaling," *Cell Stress and Chaperones*, vol. 9, no. 1, pp. 4–20, 2004.

[24] B. D. Hollingshead, J. R. Petrusis, and G. H. Perdew, "The aryl hydrocarbon (Ah) receptor transcriptional regulator hepatitis B virus X-associated protein 2 antagonizes p23 binding to Ah receptor-Hsp90 complexes and is dispensable for receptor function," *The Journal of Biological Chemistry*, vol. 279, no. 44, pp. 45652–45661, 2004.

[25] B. D. Abbott, M. R. Probst, G. H. Perdew, and A. R. Buckalew, "AH receptor, ARNT, glucocorticoid receptor, EGF receptor, EGF, TGF α, TGF β 1, TGF β 2, and TGF β 3 expression in human embryonic palate, and effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)," *Teratology*, vol. 58, no. 2, pp. 30–43, 1998.

[26] T. V. Beischlag and G. H. Perdew, "ERα-AHR-ARNT protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription," *The Journal of Biological Chemistry*, vol. 280, no. 22, pp. 21607–21611, 2005.

[27] L. Biegel and S. Safe, "Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on cell growth and the secretion of the estrogen-induced 34-, 52- and 160-kDa proteins in human breast cancer cells," *Journal of Steroid Biochemistry and Molecular Biology*, vol. 37, no. 5, pp. 725–732, 1990.

[28] D. M. Tappenden, S. G. Lynn, R. B. Crawford et al., "The aryl hydrocarbon receptor interacts with ATP5a1, a subunit of the ATP synthase complex, and modulates mitochondrial function," *Toxicology and Applied Pharmacology*, vol. 254, no. 3, pp. 299–310, 2011.

[29] J. V. Schmidt and C. A. Bradfield, "AH receptor signaling pathways," *Annual Review of Cell and Developmental Biology*, vol. 12, pp. 55–89, 1996.

[30] O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, "Protein measurement with the Folin phenol reagent," *The Journal of Biological Chemistry*, vol. 193, no. 1, pp. 265–275, 1951.

[31] A. Vengellur and J. J. LaPres, "The role of hypoxia inducible factor Iα in cobalt chloride induced cell death in mouse embryonic fibroblasts," *Toxicological Sciences*, vol. 82, no. 2, pp. 638–646, 2004.

[32] A. Shevchenko, M. Wilm, O. Vorm, and M. Mann, "Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels," *Analytical Chemistry*, vol. 68, no. 5, pp. 850–858, 1996.

[33] K. Ohmura, N. Kohno, Y. Kobayashi et al., "A homologue of pancreatic trypsin is localized in the acrosome of mammalian sperm and is released during acrosome reaction," *The Journal of Biological Chemistry*, vol. 274, no. 41, pp. 29426–29432, 1999.

[34] L. Jia, J. Kaur, and R. A. Stuart, "Mapping of the Saccharomyces cerevisiae oral-mitochondrial ribosome interface and identification of MrpL40, a ribosomal protein in close proximity to oxal and critical for oxidative phosphorylation complex assembly," *Eukaryotic Cell*, vol. 8, no. 11, pp. 1792–1802, 2009.

[35] R. Accardi, E. Oxelmark, N. Jauniaux, V. de Pinto, A. Marchini, and M. Tommasino, "High levels of the mitochondrial large ribosomal subunit protein 40 prevent loss of mitochondrial DNA in null mmlf Saccharomyces cerevisiae cells," *Yeast*, vol. 21, no. 7, pp. 539–548, 2004.

[36] T. M. Maynard, D. W. Meechan, M. L. Dudevoir et al., "Mitochondrial localization and function of a subset of 22q11 deletion
syndrome candidate genes,” *Molecular and Cellular Neuroscience*, vol. 39, no. 3, pp. 439–451, 2008.

[37] B. Funke, A. Puech, B. Saint-Jore, R. Pandita, A. Skoulitchi, and B. Morrow, “Isolation and characterization of a human gene containing a nuclear localization signal from the critical region for velo-cardio-facial syndrome on 22q11,” *Genomics*, vol. 53, no. 2, pp. 146–154, 1998.

[38] C. J. Auernhammer, N. B. Isele, F. B. Kopp et al., “Novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) stimulates corticotroph function via a signal transducer and activator of transcription-dependent mechanism negatively regulated by suppressor of cytokine signaling-3,” *Endocrinology*, vol. 144, no. 4, pp. 1202–1210, 2003.

[39] E. Lelièvre, H. Plun-Favreau, S. Chevalier et al., “Signaling pathways recruited by the cardiotrophin-like cytokine/cytokine-like factor-1 composite cytokine. Specific requirement of the membrane-bound form of ciliary neurotrophic factor receptor α component,” *The Journal of Biological Chemistry*, vol. 276, no. 25, pp. 22476–22484, 2001.

[40] G. Blot, S. Lopez-Vergès, C. Treand et al., “Luman, a new partner of HIV-1 TM gp41, interferes with Tat-mediated transcription of the HIV-1 LTR,” *Journal of Molecular Biology*, vol. 364, no. 5, pp. 1034–1047, 2006.

[41] M. W. Lee, D. Chanda, J. Yang et al., “Regulation of hepatic gluconeogenesis by an ER-bound transcription factor, CREBH,” *Cell Metabolism*, vol. 11, no. 4, pp. 331–339, 2010.

[42] C. N. Adra, J. Donato, R. Badovinac et al., “SMARCAD1, a novel human helicase family-defining member associated with genetic instability: cloning, expression, and mapping to 4q22-q23, a band rich in breakpoints and deletion mutants involved in several human diseases,” *Genomics*, vol. 69, no. 2, pp. 162–173, 2000.

[43] K. Moldave, “Eukaryotic protein synthesis,” *Annual Review of Biochemistry*, vol. 54, pp. 1109–1149, 1985.

[44] C. Kahler, H. Weber, C. Mogler et al., “Increased expression of ALCAM in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse,” *The British Journal of Cancer*, vol. 101, no. 3, pp. 457–464, 2009.

[45] V. Kulasingam, Y. Zheng, A. Soosaipillai, A. E. Leon, M. Gion, and E. P. Diamandis, “Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer,” *International Journal of Cancer*, vol. 125, no. 1, pp. 9–14, 2009.

[46] S. F. Ofori-Acquah and J. A. King, “Activated leukocyte cell adhesion molecule: a new parado in cancer,” *Translational Research*, vol. 151, no. 3, pp. 122–128, 2008.

[47] S. Song, S. Kole, P. Precht, M. J. Pazin, and M. Bernier, “Activation of heat shock factor 1 plays a role in pyrrolidine dithiocarbamate-mediated expression of the co-chaperone BAG3,” *International Journal of Biochemistry and Cell Biology*, vol. 42, no. 11, pp. 1856–1863, 2010.

[48] A. K. McCollum, G. Casagrande, and E. C. Kohn, “Caught in the middle: the role of Bag3 in disease,” *Biochemical Journal*, vol. 425, no. 1, pp. e1–e3, 2010.

[49] M. Iwasaki, S. Homma, A. Hishiya, S. J. Dolezal, J. C. Reed, and S. Takayama, “BAG3 regulates motility and adhesion of epithelial cancer cells,” *Cancer Research*, vol. 67, no. 21, pp. 10252–10259, 2007.

[50] A. Rosati, E. Di Salle, L. Lubierto et al., “Identification of a Btk-BAG3 complex induced by oxidative stress,” *Leukemia*, vol. 23, no. 4, pp. 823–824, 2009.

[51] S. Hashimoto, A. Hashimoto, A. Yamada, Y. Onodera, and H. Sabe, “Assays and properties of the ArfGAPs, AMAP1 and AMAP2, in Arf6 function,” *Methods in Enzymology*, vol. 404, pp. 216–231, 2006.

[52] C. Matsui, S. Kaieda, T. Ikegami, and Y. Mimori-Kiyosue, “Identification of a link between the SAMP repeats of adenomatous polyposis coli tumor suppressor and the Src homology 3 domain of DDEF,” *The Journal of Biological Chemistry*, vol. 283, no. 47, pp. 33006–33020, 2008.

[53] R. K. Naz and L. Dhandapani, “Identification of human sperm proteins that interact with human zona pellucida3 (ZP3) using yeast two-hybrid system,” *Journal of Reproductive Immunology*, vol. 84, no. 1, pp. 24–31, 2010.

[54] N. I. Kerkvliet, “Immunological effects of chlorinated dibenzo-p-dioxins,” *Environmental Health Perspectives*, vol. 103, no. 9, pp. 47–53, 1995.

[55] J. G. Vos and H. van Loveren, “Markers for immunotoxic effects in rodents and man,” *Toxicology Letters*, vol. 82-83, pp. 385–394, 1995.

[56] A. Puga, C. Ma, and J. L. Marlowe, “The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways,” *Biochemical Pharmacology*, vol. 77, no. 4, pp. 713–722, 2009.

[57] H. A. Aly and O. Domenech, “Cytotoxicity and mitochondrial dysfunction of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in isolated rat hepatocytes,” *Toxicology Letters*, vol. 191, no. 1, pp. 79–87, 2009.

[58] D. L. Alexander, S. E. Eltom, and C. R. Jefcoate, “Ah receptor regulation of CYP1B1 expression in primary mouse embryo-derived cells,” *Cancer Research*, vol. 57, no. 20, pp. 4498–4506, 1997.

[59] G. Yao, M. Craven, N. Drinkwater, and C. A. Bradfield, “Interac tion networks in yeast define and enumerate the signaling steps of the vertebrate aryl hydrocarbon receptor,” *PLoS Biology*, vol. 2, no. 3, article e65, 2004.

[60] Y. Tian, A. B. Rabson, and M. A. Gallo, “Ah receptor and NF-κB interactions: mechanisms and physiological implications,” *Chemico-Biological Interactions*, vol. 141, no. 1-2, pp. 97–115, 2002.

[61] P. L. Roulhac, J. M. Ward, J. W. Thompson et al., “Microproteomics: quantitative proteomic profiling of small numbers of laser-captured cells,” *Cold Spring Harbor Protocols*, no. 2, 2011.

[62] P. Puri, A. Acker-Palmer, R. Stahler, Y. Chen, D. Kline, and S. Vijayaraghavan, “Identification of testsis14-3-3 binding proteins by tandem affinity purification,” *Spermatogenesis*, vol. 1, no. 4, pp. 354–365, 2011.

[63] P. Agrawal, K. Yu, A. R. Salomon, and J. M. Sedivy, “Proteomic profiling of Myc-associated proteins,” *Cell Cycle*, vol. 9, no. 24, pp. 4908–4921, 2010.

[64] S. J. Stohs, “Oxidative stress induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD),” *Free Radical Biology and Medicine*, vol. 9, no. 1, pp. 79–90, 1990.

[65] H. G. Shertzer, M. B. Center, D. Shen, D. W. Nebert, Y. Chen, and T. P. Dalton, “TCDD decreases ATP levels and increases reactive oxygen production through changes in mitochondrial FOF1-ATP synthase and ubiquinone,” *Toxicology and Applied Pharmacology*, vol. 217, no. 3, pp. 363–374, 2006.

[66] A. Rosati, A. Leone, L. Del Valle, S. Amini, K. Khalili, and M. C. Turco, “Evidence for BAG3 modulation of HIV-1 gene transcription,” *Journal of Cellular Physiology*, vol. 210, no. 3, pp. 676–683, 2007.

[67] A. K. Lund, M. B. Goens, N. L. Kanagy, and M. K. Walker, “Cardiac hypertrophy in aryl hydrocarbon receptor null mice is correlated with elevated angiotensin II, endothelin-1, and mean
arterial blood pressure,” *Toxicology and Applied Pharmacology*, vol. 193, no. 2, pp. 177–187, 2003.

[68] D. L. Morris, H. G. Jeong, S. D. Jordan, N. E. Kaminski, and M. P. Holsapple, “Characterization of the effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin in B6C3F1 and DBA/2 mice following single and repeated exposures,” *Archives of Toxicology*, vol. 72, no. 3, pp. 157–168, 1998.

[69] C. E. W. Sulentic, M. P. Holsapple, and N. E. Kaminski, “Aryl hydrocarbon receptor-dependent suppression by 2,3,7,8-tetrachlorodibenzo-p-dioxin of IgM secretion in activated B cells,” *Molecular Pharmacology*, vol. 53, no. 4, pp. 623–629, 1998.